Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation
Journal of Gastrointestinal Cancer · 2024
DOI: 10.1007/s12029-024-01072-0 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Gastrointestinal Cancer, 2024. Verfasst von Benjamin E Ueberroth und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, MS 8117, Aurora, CO, 80045, USA. b…. Hauptthemen laut MEDLINE: Imidazoles, Oximes, Proto-Oncogene Proteins B-raf, Pancreatic Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose
Treatment of metastatic pancreatic neuroendocrine tumors (pancNETs), particularly grade 2 (G2) and grade 3 (G3), often presents a dilemma in choosing from multiple similarly efficacious therapies. Data on targeted therapies for these tumor types is limited, and this report presents BRAF-targeted therapy as a therapeutic option for metastatic pancNET G3.
Methods
This is a case report of a patient with G3 pancNET metastatic to the liver, lung, lymph node, and scalp (soft tissue) treated with dabrafenib/trametinib (D/T) in the presence of a BRAF V600E mutation detected in tumor tissue.
Results
This patient has demonstrated an ongoing partial response to therapy at all involved sites for nearly 15 months with minimal side effects attributable to D/T.
Conclusion
Dabrafenib/trametinib therapy for BRAF-mutated metastatic pancNETs provides a novel treatment option and, especially in the G3 setting, should be considered a first-line option. Tumor testing for actionable mutations should be undertaken at the time of diagnosis and/or progression to identify novel therapeutic avenues in these rare tumors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, MS 8117, Aurora, CO, 80045, USA. benjamin.ueberroth@cuanschutz.edu.
- Division of Medical Oncology, Department of Medicine, University of Colorado School of Medicine, 12801 E 17th Ave, MS 8117, Aurora, CO, 80045, USA.
Zitieren
APA
Ueberroth, B. E., Lieu, C. H., & Lentz, R. W. (2024). Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01072-0
Vancouver
Ueberroth BE, Lieu CH, Lentz RW. Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation. Journal of Gastrointestinal Cancer. 2024. doi:10.1007/s12029-024-01072-0
BibTeX
@article{Ueberroth2024,
author = {Ueberroth, Benjamin E and Lieu, Christopher H and Lentz, Robert W},
title = {Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation},
journal = {Journal of Gastrointestinal Cancer},
year = {2024},
doi = {10.1007/s12029-024-01072-0}
}
EUVIMED